About Us
Better knock-ins, better cell lines, better science.
Oscar Perez-Leal, MD and Matt Handel established ExpressCells in 2018 with the mission to improve drug development and basic biological research by creating better cell lines. We do so using genetic engineering technology invented by Dr. Perez at the Temple University School of Pharmacy. Our primary focus is on creating research tools that will speed drug discovery and provide better disease models for basic researchers. The company is a proud member of the growing Philadelphia life sciences community and our labs are located at Biolabs at CIC in University City, Philadelphia.
ExpressCells has raised several rounds of financing. Our investors include:
Ben Franklin Technology Partners
Central Texas Angel Network
Keiretsu Forum Mid-Atlantic
MIT Alumni Angels of Northern California
Robin Hood Ventures
Rowan Innovation Venture Fund
Tech Coast Angels
Berkeley Angel Network
Management
Board of Directors
Contact Us
"The ExpressCells CRISPR-edited cell line contributed greatly to our COVID-19 related work and will eventually lead to a publication. Not only did ExpressCells deliver the cells quickly, the CRISPR-edited cell pool exhibited such high level overexpression that a clonal cell line was not required. We appreciate the quality of ExpressCells' work and their team's responsiveness."
Aaron Sato, PhD, Chief Scientific Officer, Twist Biosciences
"I will be happy to work with ExpressCells again. We have plans for using this type of cell in many experiments and will use ExpressCells for our future projects."
Somin Eunice Lee, Ph.D., University of Michigan
Better knock-ins. Better cell lines. Better science.
